About ReeLabs
ReeLabs is a Healthcare company based in Mumbai (India) founded in 2009. It offers stem cell banking from various sources and therapy for medical treatments. It operates on a B2C and B2B model. The company has 45 employees. Its website reelabs.com draws about 11 thousand monthly visits. Its Indian entity Reelabs Private Limited reported revenue of ₹17.69 Cr. ReeLabs offers products and services including Stem Cell Banking, Stem Cell Therapy, and Anti-Ageing Therapy. Its focus areas include Stem Cell Technology, Therapy, Disease Treatment and Banking. Its competitors include NuVasive, Ensoma, StemCyte, Nohla Therapeutics and Immunis and 2 more; 6 of its 7 listed competitors have raised funding.
Company details
ReeLabs specializes in stem cell banking from sources like umbilical cord, amniotic fluid, and placenta, using advanced technology for high cell viability. They provide therapy for diseases such as leukaemia and osteoarthritis, partnering with over 300 hospitals across India. Based in Mumbai, they have served over 100,000 people through innovative regenerative medicine services.
- Headquarters Mumbai, India
- Employees 45
- SectorsHealthcare
- Phone•••• ••••
- Website reelabs.com
- Social LinkedIn X Facebook Instagram YouTube
- Legal Name Reelabs Private Limited
- Date of Incorporation 23 Feb, 2009
- Jurisdiction Raigarh, Maharashtra, India
- Annual Revenue₹17.69 Cr
FY 2024 · -11% YoY
- Net Profit₹1.26 Cr
FY 2024 · 7% margin
- EBITDA₹3.48 Cr
FY 2024 · 20% margin
- Employee Count45
Associated legal entities of ReeLabs
ReeLabs operates through Reelabs Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Reelabs Private Limited CIN U85100MH2009PTC190531 | Active | 23 Feb 2009 | Mumbai, Maharashtra | ₹17.7 Cr | 45 | 3 | View details |
Products & Services of ReeLabs
ReeLabs offers a comprehensive portfolio of products and services, including Stem Cell Banking, Stem Cell Therapy, and Anti-Ageing Therapy.
Service for storing stem cells from multiple sources for future treatments.
Treatment using stem cells for diseases like leukaemia and osteoarthritis.
Uses stem cells to address ageing-related conditions and biological testing.
Apps and channels of ReeLabs
its YouTube channel ReeLabs has 466 subscribers and 29 videos.
Videos from ReeLabs
The most watched videos on ReeLabs's YouTube channel, ReeLabs (466 subscribers). Click a video to play it here.
More on ReeLabs.
Board of directors of Reelabs Private Limited (ReeLabs)
Reelabs Private Limited is the primary company behind ReeLabs. The board of Reelabs Private Limited currently have 3 directors; the longest-serving is Rohit Ramchandra Kulkarni, appointed in 2009.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Rohit Ramchandra Kulkarni DIN 02454375 | Director | 23 Feb 2009 | 17 yrs 7 mo | Reelabs Private Limited |
| Abhijit Shyamsunder Bopardikar DIN 02454406 | Director | 23 Feb 2009 | 17 yrs 7 mo | Reelabs Private Limited |
| Sunil Haripant Pophale DIN 00064412 | Managing Director | 23 Feb 2009 | 17 yrs 7 mo | Reelabs Private Limited |
Financials of ReeLabs
Figures of Reelabs Private Limited, the primary company behind ReeLabs, for FY 2024. Revenue was ₹17.69 Cr (-11% year on year). Net profit was ₹1.26 Cr (7% margin). EBITDA was ₹3.48 Cr (20% margin). Revenue has grown at a compounded annual rate of -25% over three years and +22% over five years.
- ₹17.69 CrRevenue · FY 2024 · -11% YoY
- ₹1.26 CrNet profit · 7% margin
- ₹3.48 CrEBITDA · 20% margin
- ₹2.23 CrPaid-up capital
- 45Employees (provident fund records)
- -25%Revenue CAGR, 3 years
- +22%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Reelabs Private Limited are on its company page.
Detailed financial statements for ReeLabs
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of ReeLabs
ReeLabs has 7 listed competitors in our database, 6 of them funded. They include NuVasive, Ensoma, StemCyte, Nohla Therapeutics and Immunis, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nuvasive.com | 1997 | San Diego, United States | $54.1M | 2,450 | Smart surgical devices for spinal surgery are developed. | |
| ensoma.com | 2019 | Boston, United States | $205M | 52 | Provider of in vivo stem cell modification technologies and vector-based drug delivery tool | |
| stemcyte.com | 1997 | Covina, United States | $23.25M | 43 | Umbilical cord blood stem cell transplantation and therapeutic products company | |
| nohlatherapeutics.com | 2015 | Seattle, United States | $120.5M | 48 | Develops stem-cell transplant solutions using umbilical cord blood as an alternative to bone-marrow transplants. | |
| immunisbiomedical.com | 2018 | Irvine, United States | $55.39M | 3 | Cell therapies for age- and disease-related immune deficits are developed. | |
| athersys.com | 1995 | United States | $74.43M | 113 | Stem Cell Therapy for the treatment of cardiovascular disease areas | |
| globalcordbloodcorp.com | 2003 | Hong Kong, China | – | – | Biobanking services for umbilical cord blood stem cells are provided. |
Detailed competitors of ReeLabs
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ReeLabs
The website of ReeLabs (reelabs.com) receives about 10.7K visits a month.
- Monthly visits10.7K
▲ 52.6% vs previous month
Websites whose visitors overlap most with ReeLabs. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
ncrm.org | ncrm.org | 100% | – | #6,096,769 | – |
jeevan.org | jeevan.org | 97% | – | – | – |
modernreflexology.com | modernreflexology.com | 67% | – | – | – |
stemcellresearchnews.net | stemcellresearchnews.net | 61% | – | – | – |
| smartcells.com | 61% | 11.3K | #1,950,577 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for ReeLabs
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Cell Therapy
10 companies that operate in the same segment as ReeLabs (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 253 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Reelabs
Complete news archive for ReeLabs
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ReeLabs
ReeLabs was founded in 2009.
ReeLabs is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
ReeLabs has 45 employees.
The primary company behind ReeLabs, Reelabs Private Limited, reported revenue of ₹17.69 Cr for FY 2024, down 11% year on year.
ReeLabs specializes in stem cell banking from sources like umbilical cord, amniotic fluid, and placenta, using advanced technology for high cell viability. They provide therapy for diseases such as leukaemia and osteoarthritis, partnering with over 300 hospitals across India. Based in Mumbai, they have served over 100,000 people through innovative regenerative medicine services.
ReeLabs offers Stem Cell Banking, Stem Cell Therapy, and Anti-Ageing Therapy.
ReeLabs operates through Reelabs Private Limited.
The legal entities of ReeLabs currently have 3 directors, including Rohit Ramchandra Kulkarni, Abhijit Shyamsunder Bopardikar, Sunil Haripant Pophale.